Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
IBRX 
Immunitybio Inc (IBRX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: IBRX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $10.2
1 Year Target Price $10.2
| 3 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -77.07% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.20B USD | Price to earnings Ratio - | 1Y Target Price 10.2 |
Price to earnings Ratio - | 1Y Target Price 10.2 | ||
Volume (30-day avg) 5 | Beta -0.07 | 52 Weeks Range 1.83 - 7.48 | Updated Date 08/29/2025 |
52 Weeks Range 1.83 - 7.48 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.48 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-05 | When - | Estimate -0.11 | Actual -0.1 |
Profitability
Profit Margin - | Operating Margin (TTM) -269.76% |
Management Effectiveness
Return on Assets (TTM) -42.14% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 2584101416 | Price to Sales(TTM) 38.91 |
Enterprise Value 2584101416 | Price to Sales(TTM) 38.91 | ||
Enterprise Value to Revenue 45.66 | Enterprise Value to EBITDA -8.99 | Shares Outstanding 945254976 | Shares Floating 193559802 |
Shares Outstanding 945254976 | Shares Floating 193559802 | ||
Percent Insiders 69.2 | Percent Institutions 13.24 |
Upturn AI SWOT
Immunitybio Inc
Company Overview
History and Background
ImmunityBio, Inc. (formerly NantKwest, Inc.) was founded in 2014. It focuses on developing immunotherapies for cancer and infectious diseases. The company has grown through acquisitions and strategic partnerships to expand its pipeline and technological capabilities.
Core Business Areas
- Oncology: Development and commercialization of novel immunotherapies for various cancers, including bladder cancer, pancreatic cancer, and lung cancer.
- Infectious Diseases: Research and development of vaccines and immunotherapies for infectious diseases, such as HIV and COVID-19.
- Cell Therapy: Development of cell-based therapies using natural killer (NK) cells and T cells to target cancer and infectious diseases.
Leadership and Structure
Dr. Patrick Soon-Shiong is the Executive Chairman and Global Chief Scientific and Medical Officer. The company has a typical hierarchical structure with departments focusing on research, development, manufacturing, and commercialization.
Top Products and Market Share
Key Offerings
- Anktiva (N-803): An IL-15 superagonist immunotherapy currently under FDA review for non-muscle invasive bladder cancer (NMIBC) BCG-unresponsive. If approved, it would compete with companies like Merck (Keytruda) and Ferring Pharmaceuticals (Adstiladrin). Revenue will depend on market penetration after approval, and no market share data is currently available since it is not yet approved.
- Aldoxorubicin: A chemotherapeutic agent being developed for various cancers. It is in clinical trials. Competitors include traditional chemotherapy drugs and newer targeted therapies. No market share or number of users available.
Market Dynamics
Industry Overview
The immunotherapy market is rapidly growing, driven by advancements in cancer research and the development of novel therapies. The market is competitive, with many pharmaceutical companies and biotech firms developing immunotherapies.
Positioning
ImmunityBio is positioned as an innovative immunotherapy company focusing on NK cell and T cell therapies. Its competitive advantage lies in its proprietary technologies and its broad pipeline of product candidates.
Total Addressable Market (TAM)
The global immunotherapy market is estimated to reach hundreds of billions of dollars in the coming years. ImmunityBio is positioned to capture a portion of this market with its diverse pipeline and innovative technologies. Specific projections will depend on approval and successful launch of its lead candidates
Upturn SWOT Analysis
Strengths
- Proprietary immunotherapy platforms
- Extensive clinical pipeline
- Experienced leadership team
- Potential first-in-class therapies
Weaknesses
- High cash burn rate
- Reliance on regulatory approvals
- Competition from established pharmaceutical companies
- History of losses and accumulated deficit
Opportunities
- Regulatory approval of Anktiva
- Expansion of clinical trials into new indications
- Strategic partnerships with pharmaceutical companies
- Increased adoption of immunotherapy in cancer treatment
Threats
- Failure to obtain regulatory approvals
- Clinical trial setbacks
- Competition from biosimilars
- Changes in healthcare regulations
Competitors and Market Share
Key Competitors
- MRK
- BMY
- PFE
Competitive Landscape
ImmunityBio faces strong competition from established pharmaceutical companies with greater resources and broader product portfolios. Its competitive advantage lies in its novel technologies and targeted approach to immunotherapy.
Major Acquisitions
Altor BioScience
- Year: 2019
- Acquisition Price (USD millions): 290
- Strategic Rationale: Acquisition of Altor BioScience expanded ImmunityBio's pipeline of immunotherapies and strengthened its intellectual property portfolio.
Growth Trajectory and Initiatives
Historical Growth: ImmunityBio has experienced growth in its clinical pipeline and partnerships. Revenue growth has been variable due to the nature of licensing agreements.
Future Projections: Future growth is dependent on the successful development and commercialization of its product candidates, particularly Anktiva. Analyst estimates vary depending on the likelihood of regulatory approval and market penetration.
Recent Initiatives: Recent initiatives include advancing Anktiva through regulatory review, expanding clinical trials for other product candidates, and forging strategic partnerships.
Summary
ImmunityBio is a clinical-stage immunotherapy company with a promising pipeline, especially Anktiva. Its financial health is a concern due to consistent losses and reliance on external funding. Successful regulatory approvals and commercialization of its products are critical for its future success. It operates in a highly competitive market and requires vigilant management of its expenses and strategic partnerships.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Press releases
- Analyst reports
- Third-party market research reports
Disclaimers:
This analysis is based on available information and is not financial advice. Investment decisions should be made after consulting with a qualified financial advisor. Market share data is estimated and may vary. Financial data is current as of the time of writing and may change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Immunitybio Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2015-07-28 | President, CEO & Director Mr. Richard Gerald Adcock | ||
Sector Healthcare | Industry Biotechnology | Full time employees 685 | Website https://immunitybio.com |
Full time employees 685 | Website https://immunitybio.com | ||
ImmunityBio, Inc., a commercial stage biotechnology company, develops next-generation therapies that bolster the natural immune systems to defeat cancers and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeiGene, Ltd. ImmunityBio, Inc. is based in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.